Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01061515 · ClinicalTrials.gov registry record · Phase 1
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
A Phase 1 study of Carcinoma, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01061515: Active Phase 1 study of Carcinoma, sponsored by Washington University School of Medicine.
NCT01061515 is a Phase 1 study of Carcinoma that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 21 participants, below the 254-participant average among 29 other Carcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01061515, a Phase 1 study of Carcinoma, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to test escalating doses of intraperitoneal (IP) oxaliplatin in conjunction with systemic bevacizumab and capecitabine in patients with Peritoneal Carcinomatosis (PC) from either appendiceal or colorectal adenocarcinoma that have been adequately cytoreduced and have undergone a peritoneal scan demonstrating patency of at least one of the intraperitoneal ports that were placed at the time of debulking.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Capecitabine
- DRUG Intraperitoneal Oxaliplatin
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-05-10 |
| Est. Completion | 2026-09-27 |
| Phase | Phase 1 |
What the registry record for NCT01061515 still lists
NCT01061515 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 254-participant average among 29 other Carcinoma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01061515 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT01061515 about?
NCT01061515 is a clinical study titled "Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer". This study is to test escalating doses of intraperitoneal (IP) oxaliplatin in conjunction with systemic bevacizumab and capecitabine in patients with Peritoneal Carcinomatosis (PC) from either appendiceal or colorectal adenocarcinoma that have been adequately cytoreduced and have undergone a periton...
What is the current status of trial NCT01061515?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2011-05-10. Estimated completion is 2026-09-27.
What conditions does trial NCT01061515 study?
This clinical trial studies the following conditions: Carcinoma.
What interventions are being tested in trial NCT01061515?
The interventions under investigation include: Bevacizumab (DRUG), Capecitabine (DRUG), Intraperitoneal Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT01061515?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01061515 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01061515's enrollment target sits among peer trials
21 26th of 29 higher than 3 of 29 other Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
RECRUITING · Phase 1
-
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
RECRUITING · Phase 1
-
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
-
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
-
Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI